Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioMark Diagnostics Inc C.BUX

Alternate Symbol(s):  BMKDF

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring... see more

Recent & Breaking News (CSE:BUX)

BioMark to Present at the Virtual Biotech Showcase and the Digital RESI JPM 2022 Conferences

Newsfile January 10, 2022

BioMark (CSE:BUX) to collaborate with AstraZeneca and Pfizer Canada to improve early detection of lung cancer

Julia Kennedy  November 30, 2021

BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer

Newsfile November 30, 2021

BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term

Newsfile November 25, 2021

BioMark Secures Funding to Accelerate Development of Its Liquid Biopsy Assay in Quebec

Newsfile November 16, 2021

BioMark (CSE:BUX) supports Lung Cancer Awareness Month

Brieanna McCutcheon  November 10, 2021

BioMark Recognizes and Supports the Lung Cancer Awareness Month

Newsfile November 10, 2021

Diagnostic and Therapeutic Benefits of BioMark's Cancer Marker Featured in Two Poster Presentations at the Canadian Cancer Research Conference

Newsfile November 8, 2021

Liquid Biopsy Company BioMark to Present at the 3rd Annual Congress of the International Society of Liquid Biopsy to Be Held October 22, 2021

Newsfile October 18, 2021

BioMark Diagnostics (CSE:BUX) expands treatment response trial

Jocelyn Aspa June 29, 2021

Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patients Receiving Immunotherapy

Newsfile June 29, 2021

5 Top Stories of the week: Digimax Global (CSE:DIGI), Psybio Therapeutics (TSXV:PSYB), Sixth Wave Innovations (CSE:SIXW), EV Battery Tech (CSE:ACDC), BioMark (CSE:BUX)

Jocelyn Aspa June 4, 2021

BioMark receives $825K grant for lung cancer research

Trevor Abes  June 1, 2021

BioMark Receives $825K Grant to Develop Its Liquid Biopsy Assay for Lung Cancer Screening

Newsfile June 1, 2021

BioMark Announces Change of Auditor

Newsfile May 31, 2021

BioMark (CSE:BUX) to open diagnostic laboratory in Québec

Julia Kennedy  April 29, 2021

Biomark to Open a Diagnostic Laboratory in Quebec

Newsfile April 29, 2021

BioMark Announces Exercise of Warrants and Gain DTC Eligibility for Its Common Shares

Newsfile April 21, 2021

Biomark's Collaborator Receives Funding to Validate Its Biomarker Panel for the Early Detection of Lung Cancer

Newsfile March 16, 2021

BioMark Grants Options

Newsfile March 2, 2021